Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > BUSINESS
BUSINESS
- Eisai to Dissolve, Absorb Its Diagnostics Research Subsidiary Palma Bee’Z
October 12, 2012
- AVEO Files NDA for Tivozanib in US: Astellas
October 12, 2012
- Ajinomoto, Astellas to Codevelop Nateglinide for Combination Use with DPP-4 Inhibitors
October 11, 2012
- MTPC, Kureha Fail to Meet Primary Goal in Global PIII Studies for Kremezin
October 11, 2012
- Kyorin to Transfer Pekiron to Galderma
October 11, 2012
- Sanofi Files Lawsuit against 3 Companies for Approved Allegra Generics
October 11, 2012
- Policy Directions Headed for “Price Cuts for Long-Listed Drugs,” “Price Control for High Priced Drugs”: Prof. Nakamura of Keio Univ.
October 11, 2012
- Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
- Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
- Daiichi Sankyo Espha Considers Manufacturing Generics to Be Listed in 2014 at Ranbaxy’s Factory
October 10, 2012
- Chugai Files Avastin for Ovarian Cancer
October 10, 2012
- Ethical Drug Sales Down 1.4% in August: Crecon Report
October 10, 2012
- Companies Voice Concern over Implementation of Bar Code Labeling Due to Few Design Companies
October 9, 2012
- Zeria Terminates Development of Allergic Rhinitis Treatment
October 9, 2012
- Towa Consolidates Distribution Bases to 2 Sites in Eastern and Western Japan
October 9, 2012
- Takeda to Acquire LigoCyte of the US to Strengthen Vaccine Business
October 9, 2012
- Takeda Appeals to IP High Court in Actos Patent Lawsuit
October 9, 2012
- Ono, Carna Biosciences Conclude Capital Alliance Agreement, Making Ono Carna’s Largest Shareholder
October 9, 2012
- GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation
October 8, 2012
- All Sawai MRs to Use iPads, First for Generics Maker
October 5, 2012
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…